Stilnoct 10mg Film-Coated Tablets

  • Name:

    Stilnoct 10mg Film-Coated Tablets

  • Company:
    info
  • Active Ingredients:

    Zolpidem tartrate

  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 19/03/20

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 19/3/2020

Click on this link to Download PDF directly

SANOFI

SANOFI

Company Products

Medicine NameActive Ingredients
Medicine Name Adenocor Active Ingredients Adenosine
Medicine Name Amaryl 1mg Tablets Active Ingredients Glimepiride
Medicine Name Amaryl 3mg Tablets Active Ingredients Glimepiride
Medicine Name Anthisan Cream Active Ingredients Mepyramine Maleate
Medicine Name Apidra 100 units/ml solution for injection in a cartridge Active Ingredients Insulin Glulisine
Medicine Name Apidra 100 Units/ml solution for injection in a vial Active Ingredients Insulin Glulisine
Medicine Name Apidra SoloStar 100 units/ml solution for injection in a pre-filled pen Active Ingredients Insulin Glulisine
Medicine Name Aprovel 150mg film-coated tablets Active Ingredients Irbesartan
Medicine Name Aprovel 300mg film-coated tablets Active Ingredients Irbesartan
Medicine Name Aprovel 75mg film-coated tablets Active Ingredients Irbesartan
Medicine Name Arava 10 mg film-coated tablets Active Ingredients Leflunomide
Medicine Name Arava 20 mg film-coated tablets Active Ingredients Leflunomide
Medicine Name Bisolvon Oral Solution Active Ingredients Bromhexine hydrochloride
Medicine Name Brolene 0.1%w/v Eye Drops Solution Active Ingredients Propamidine Isethionate
Medicine Name Brolene 0.15% w/w Eye Ointment Active Ingredients Dibromopropamidine Isethionate
Medicine Name Buscopan 10 mg Coated Tablets Active Ingredients hyoscine butylbromide
Medicine Name Buscopan Ampoules Active Ingredients hyoscine butylbromide
Medicine Name Buscopan Rx 10mg Coated Tablets Active Ingredients hyoscine butylbromide
Medicine Name Calcium Resonium Active Ingredients Calcium polystyrene sulfonate
Medicine Name Cerubidin 20mg Powder for Solution for Injection Active Ingredients daunorubicin hydrochloride
Medicine Name Cidomycin Paediatric 20mg/2ml Solution For Injection Active Ingredients Gentamicin sulfate
Medicine Name Claforan Powder for Solution for Injection 1g Active Ingredients Cefotaxime sodium
Medicine Name Claforan Powder for Solution for Injection 500mg Active Ingredients Cefotaxime sodium
Medicine Name Clexane 10,000 IU (100mg)/1ml Solution for Injection Active Ingredients Enoxaparin sodium
Medicine Name Clexane 2,000 IU (20 mg) /0.2 mL Solution for Injection Active Ingredients Enoxaparin sodium
1 - 0 of 176 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 19 March 2020 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 6.5 - Nature and contents of container

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 19 March 2020 PIL

Reasons for updating

  • Change to section 4 - possible side effects
  • Change to section 4 - how to report a side effect
  • Change to section 6 - what the product contains
  • Change to section 6 - what the product looks like and pack contents

Updated on 9 May 2019 PIL

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions

Updated on 8 May 2019 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

4.4  Special warnings and precautions for use

  • Suicidal ideation/suicide attempt/suicide and depression
    Some epidemiological studies suggest an increased incidence of suicidal ideation, suicide attempt and suicide in patients with or without depression, and treated with benzodiazepines and other hypnotics, including zolpidem. However, a causal relationship has not been established.

 

Updated on 22 January 2019 PIL

Reasons for updating

  • Change to Section 1 - what the product is
  • Change to section 1 - what the product is used for
  • Change to section 2 - what you need to know - warnings and precautions

Updated on 22 January 2019 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

The duration of treatment should usually vary from a few days to two weeks with a maximum        of four weeks including tapering off where clinically appropriate.    

 

Treatment should be as short as possible. It should not exceed four weeks including the period of tapering off. In certain cases extension beyond the maximum treatment period may be necessary; if so, extension beyond the maximum treatment period should not take place without re-evaluation of the patient's status, since the risk of abuse and dependence increases with the duration of treatment (see Section 4.4).

 

Special Populations

 

 

  • Hepatic Insufficiency
    Mild to moderate Hepatic Impairment/ insufficiency - See dose recommendations (See Section 4.2, 4.3 and Section 4.8).
     
  • Dependence
    Use of zolpidem may lead to the development of abuse and/or physical and psychological dependence. The risk of dependence increases with dose and duration of treatment. The risk of abuse and dependence is also greater in patients with a history of psychiatric disorders and/or alcohol, substance or drug abuse. zolpidem should be used with extreme caution in patients with current or a history of alcohol, substance or drug abuse or dependence.
     
    If physical dependence is developed, a sudden discontinuation of treatment will be accompanied by withdrawal symptoms. These may consist of headaches, muscle pain, extreme anxiety, tension, restlessness, confusion and irritability. In severe cases the following symptoms may occur: derealisation, depersonalisation, hyperacusis, numbness and tingling of the extremities, hypersensitivity to light, noise and physical contact, hallucinations or epileptic seizures.
     
     
    Precautions:

Updated on 12 December 2018 SmPC

Reasons for updating

  • Correction of spelling/typing errors

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Correction to that suspects is

 

Section 4.8

Updated on 12 December 2018 SmPC

Reasons for updating

  • Correction of spelling/typing errors

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.6

If Stiltnoct is prescribed to women ofchildbearing potential, she should be warned to contact herphysician about stopping the product if she intends to become or supsects that .. is pregnant

Updated on 23 November 2018 PIL

Reasons for updating

  • Change to section 2 - pregnancy, breast feeding and fertility

Updated on 23 November 2018 SmPC

Reasons for updating

  • Change to section 4.6 - Pregnancy and lactation

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

4.6       Fertility, pregnancy and lactation

Pregnancy

The use of zolpidem is not recommended during pregnancy.

 

Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity.

 

Zolpidem crosses the placenta.

 

A large amount of data on pregnant women (more than 1000 pregnancy outcomes) collected from cohort studies has not demonstrated evidence of the occurrence of malformations following exposure to benzodiazepines or benzodiazepine-like substances during the first trimester of pregnancy. However, certain case-control studies reported an increased incidence of cleft lip and palate associated with use of benzodiazepines during pregnancy.

 

Cases of reduced foetal movement and foetal heart rate variability have been described after administration of benzodiazepines or benzodiazepine-like substances during the second and/or third trimester of pregnancy. Administration of zolpidem during the late phase of pregnancy or during labour has been associated with effects on the neonate, such as hypothermia, hypotonia, feeding difficulties (‘floppy infant syndrome’), and respiratory depression, due to the pharmacological action of the product. Cases of severe neonatal respiratory depression have been reported.

 

Moreover, infants born to mothers who took sedative/hypnotic agents chronically during the latter stages of pregnancy may have developed physical dependence and may be at risk of developing withdrawal symptoms in the postnatal period. Appropriate monitoring of the newborn in the postnatal period is recommended.

 

            If Stilnoct is prescribed to a woman of childbearing potential, she should be warned to         contact her physician about stopping the product if she intends to become or suspects that          she is pregnant.

As a precautionary measure, it is preferable to avoid the use of zolpidem in pregnancy.

 

For zolpidem, no or very limited amount of data on pregnant patients are available.  Animal studies do not indicate direct harmful effects with respect to reproduction toxicity development.

 

If the product is prescribed to a woman of childbearing potential, she should be warned to contact her physician about stopping the product if she intends to become or suspects that she is pregnant.

 

If zolpidem is administered during the late phase of pregnancy, or during labour, effects on the neonate, such as hypothermia, hypotonia and moderate respiratory depression, can be expected due to the pharmacological action of the product. Cases of severe neonatal respiratory depression have been reported when zolpidem was used with other CNS depressants at the end of pregnancy.

 

Moreover, infants born to mothers who took sedative/hypnotic agents chronically during the latter stages of pregnancy may have developed physical dependence and may be at some risk of developing withdrawal symptoms in the postnatal period.

            Lactation

Small quantities of zolpidem tartrate appear in breast milk.  The use of zolpidem in nursing mothers is therefore not recommended.

4.7       Effects on ability to drive and use machines

Updated on 18 September 2018 PIL

Reasons for updating

  • Improved presentation of PIL

Updated on 17 September 2018 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

4.4.2 General information

General information relating to effects seen following administration of hypnotic agents  which should be taken into account by the prescribing physician are described belowproducts and other forms of interaction and Ssection 4.8 Undesirable effects)

4.8       Undesirable effects

Uncommon: paraesthesia, tremor, disturbance in attention, speech disorder

Not knownRare: depressed level of consciousness, disturbance in attention, speech disorder.

Common: hHallucination, agitation, nightmare, depression (See Section 4.4)..

Uncommon: confusional state, irritability, restlessness, aggression, somnambulism (See Section 4.4), euphoric mood

Rare: libido disorder

Very rare: delusion, dependence (withdrawal symptoms, or rebound effects may occur after treatment discontinuation).

Not kKnown: restlessness, aggression, delusion, anger, abnormal behaviour, somnambulism, (See section 4.4 Special warnings and precautions for use: Somnambulism and associated behaviours),dependence (drug withdrawal syndrome, or rebound effects may occur after treatment discontinuation), libido disorder, depression (see section 4.4), euphoric mood

Not knownRare: gait disturbance, drug tolerance, fall (predominantly in elderly patients and        

Not known: drug toleranc

Not KnownVery rare: respiratory depression (see section 4.4)

Not known: muscular weakness

Not knownUncommon: rash, pruritus, urticariam hyperhidrosis.

Rare: urticari

Not knownUncommon: liver enzymes elevated

Rare: , hepatocellular, cholestatic or mixed liver injury (see Sections 4.2, Section  and 4.3 and Section 4.5).

Updated on 22 August 2018 PIL

Reasons for updating

  • Change to section 4 - possible side effects
  • Change to section 4 - how to report a side effect
  • Change to section 6 - what the product contains
  • Change to section 6 - what the product looks like and pack contents

Updated on 4 January 2018 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 4 January 2018 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.4 added:-

Risk from concomitant use of opioids:

Concomitant use of Stilnoct and opioids may result in sedation, respiratory depression, coma and death. Because of these risks, concomitant prescribing of sedative medicines such as benzodiazepines or related drugs such as Stilnoct with opioids should be reserved for patients for whom alternative treatment options are not possible.

If a decision is made to prescribe Stilnoct concomitantly with opioids, the lowest effective dose should be used, and the duration of treatment should be as short as possible (see also general dose recommendation in section 4.2).

The patients should be followed closely for signs and symptoms of respiratory depression and sedation. In this respect, it is strongly recommended to inform patients and their environment to be aware of these symptoms (see section 4.5).

Section 4.5 added:-

Opioids:

The concomitant use of sedative medicines such as benzodiazepines or related drugs such as Stilnoct with opioids increases the risk of sedation, respiratory depression, coma and death because of additive CNS depressant effect. The dosage and duration of concomitant use should be limited (see section 4.4).

Updated on 22 December 2017 PIL

Reasons for updating

  • New PIL for new product

Updated on 22 December 2017 PIL

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions

Updated on 24 November 2017 SmPC

Reasons for updating

  • Change to section 3 - Pharmaceutical form
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 3

To include a statement indicating that Stilnoct 10mg film-coated tablets can be divided into equal doses.

Updated on 22 November 2017 PIL

Reasons for updating

  • Change to section 3 - how to take/use
  • Change to section 6 - date of revision

Updated on 10 July 2017 SmPC

Reasons for updating

  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 6.3 - Shelf life
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Revision date of SPC corrected to 15-June-2017

Updated on 3 July 2017 PIL

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 6 - date of revision

Updated on 30 June 2017 SmPC

Reasons for updating

  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 6.3 - Shelf life
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company



Type IAin B.II.f.1.a.1 variation for a reduction of the shelf-life to 36 months for Stilnoct (zolpidem tartrate) 10mg film-coated tablets

This variation impacts on Section 6.3 of the SmPC; however it has no effect on the labelling or patient information leaflet for Stilnoct (zolpidem tartrate) 10mg tablets.

 

This variation was implemented (TypeIAin) on 22-Jun-2017 and the impacted batch with the reduced shelf life is BN: D1505.


Type IAin.B.II.f.1.a.1 variation for a reduction of the shelf-life to 36 months.
















       

            

 




















 

      

Updated on 20 June 2017 PIL

Reasons for updating

  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 30 August 2016 PIL

Reasons for updating

  • Change to, or new use for medicine
  • Change to instructions about missed dose
  • Change to instructions about overdose
  • Change to side-effects

Updated on 19 August 2016 SmPC

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

.

Updated on 18 August 2016 PIL

Reasons for updating

  • Change to date of revision

Updated on 5 January 2015 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.2 updated:

The recommended daily dose for adults is 10 mg.

The treatment should be taken in a single intake and not be re-administered during the same night.  The recommended daily does for adults is 10mg to be taken immediately at bedtime.  The lowest effective daily dose of zolpidem should be used and must not exceed 10mg.


Section 4.4:
New paragraph:

Next-day psychomotor impairment

The risk of next-day psychomotor impairment, including impaired driving ability, is increased if:

• zolpidem is taken within less than 8 hours before performing activities that require mental alertness (see section 4.7);

• a dose higher than the recommended dose is taken;

• zolpidem is co-administered with other CNS depressants or with other drugs that increase the blood levels of zolpidem, or with alcohol or illicit drugs (see section 4.5).

 Zolpidem should be taken in a single intake immediately at bedtime and not be re-administered during the same night.


Amnesia changed:

Amnesia:

Sedative/hypnotic agents such as zolpidem may induce anterograde amnesia.  The condition occurs most often several hours after ingesting the product and therefore to reduce the risk patients should ensure that they will be able to have an uninterrupted sleep of 7-8 hours. In order to reduce the risk, patients should ensure that they will be able to have an uninterrupted sleep of 8 hours (see section 4.8).


New paragraph:

Severe Injuries

Due to its pharmacological properties, zolpidem can cause drowsiness and a decreased level of consciousness, which may lead to falls and consequently to severe injuries, see also section 4.8.

Section 4.5: changes:

Combination with CNS depressants.

Enhancement of the central depressive effect may occur in cases of concomitant use with antipsychotics (neuroleptics), hypnotics, anxiolytics/sedatives, antidepressant agents, narcotic analgesics, antiepileptic drugs, anaesthetics and sedative antihistamines. Therefore concomitant use of zolpidem with these drugs may increase drowsiness and next day psychomotor impairment, including impaired driving ability (see section 4.4 and section 4.7).  Also, isolated cases of visual hallucinations were reported in patients taking zolpidem with antidepressants including buproprion, desipramine, fluoxetine, sertraline and venlafaxine..

 

Co- administration of fluvoxamine may increase blood levels of zolpidem, concurrent use is not recommended. However, in the case of SSRI antidepressant agents (fluoxetine and sertraline), no clinically significant pharmacokinetic or pharmacodynamic interactions have been observed.

Co-administration ciprofloxacin may increase blood levels of zolpidem, concurrent use is not recommended.

 

Other drugs: When zolpidem was administered with warfarin, digoxin, ranitidine or cimetidine, no significant pharmacokinetic interactions were observed.

Section 4.7:

Vehicle drivers and machine operators should be warned that, as with other hypnotics, there may be a possible risk of drowsiness the morning after therapy. In order to minimise this risk a full night sleep (7-8 hours) is recommended.

Stilnoct has major influence on the ability to drive and use machines.

Vehicle drivers and machine operators should be warned that, as with other hypnotics, there may be a possible risk of drowsiness, prolonged reaction time, dizziness, sleepiness, blurred/double vision and reduced alertness and impaired driving the morning after therapy (see section 4.8). In order to minimise this risk a resting period of at least 8 hours is recommended between taking zolpidem and driving, using machinery and working at heights.

Driving ability impairment and behaviours such as ‘sleep-driving’ have occurred with zolpidem alone at therapeutic doses.

Furthermore, the co-administration of zolpidem with alcohol and other CNS depressants increases the risk of such behaviours (see section 4.4 and 4.5). Patients should be warned not to use alcohol or other psychoactive substances when taking zolpidem.

Section 4.8 changes:

General Disorders and administration site conditions

Common: fatigue

Not known: gait disturbance, drug tolerance, fall (predominantly in elderly patients and when zolpidem was not taken in accordance with prescribing recommendation. (See section 4.4 Special warnings and precautions for use)

 

Musculoskeletal and connective tissue disorder

Common: back pain[CCP1] 

Not known: muscular weakness.


New PV Legislation wording included.


Section 5.1: new text

The randomized trials only showed convincing evidence of efficacy of 10mg zolpidem.

In a randomized double-blind trial in 462 non-elderly healthy volunteers with transient insomnia, zolpidem 10mg decreased the mean time to fall asleep by 10 minutes compared to placebo, while for 5mg zolpidem this was 3 minutes.

In a randomized double-blind trial in 114 non-elderly patients with chronic insomnia, zolpidem 10mg decreased the mean time to fall asleep by 30 minutes compared to placebo, while for 5mg zolpidem this was 15 minutes.

 

In some patients, a lower dose of 5mg could be effective

Updated on 19 December 2014 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to drug interactions
  • Change to information about driving or using machinery
  • Change to how the medicine works
  • Change to date of revision

Updated on 27 February 2013 PIL

Reasons for updating

  • Change to side-effects
  • Change to further information section

Updated on 27 February 2013 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.9 - Overdose

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.4: 'Use in patients with a history of drugs or alcohol abuse' - paragraph moved

Section 4.6: Sub-headings inputted 'Pregnancy' and 'Lactaction'

Section 4.8: Depression added under Psychiatric disorders.  New sections 'Respiratory & mediastinal disorders' and 'Infections & infestations'

Section 4.9: Typographical error corrected

Updated on 16 August 2012 PIL

Reasons for updating

  • Improved electronic presentation

Updated on 27 September 2010 SmPC

Reasons for updating

  • Improved electronic presentation

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

legal classification updated to Product subject to prescription which may not be renewed (A)

Updated on 4 November 2009 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Update Sections
4.2, 4.4, 4.8 - typographical changes
4.6 - addition of warning on neonatal respiratory depression.

Updated on 29 October 2009 PIL

Reasons for updating

  • Change due to user-testing of patient information

Updated on 4 June 2008 PIL

Reasons for updating

  • Improved electronic presentation

Updated on 13 May 2008 SmPC

Reasons for updating

  • Correction of spelling/typing errors

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 19 December 2007 SmPC

Reasons for updating

  • Correction of spelling/typing errors

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 27 August 2007 SmPC

Reasons for updating

  • Correction of spelling/typing errors

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 8 August 2007 PIL

Reasons for updating

  • Improved electronic presentation

Updated on 8 August 2007 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Update Sections
4.2 - Addition of use in children
4.4 - Warning on use in children, amnesia
4.8 - Addtion of Immune System Disorders
4.9 - Administrative
10 - Date of revision

Updated on 24 May 2007 PIL

Reasons for updating

  • Change of licence holder

Updated on 24 May 2007 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 8 - MA number
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Update Section
7 - Change MAH to sanofi-aventis Ireland Ltd.
8 - Change PA number
10 - Date of revision

Updated on 10 January 2007 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Update Sections -
4.2 - addition of children under special populations.
4.3 - additional warning on hypersensitivity, hepatic insufficiency & respiratory insufficiency.
4.4 - additional warning on use in patients with sleep apnea, myasthenia gravis, respiratory insufficiency, depression, insomnia.
4.5 - interactions with CYP3A4 inhibitors
4.6 - additiona information on use in pregnancy
4.8 - additional undesirable effects on nervous system disorders, psychiatric disorders, general
4.9 - administrative
10 - date of revision

Updated on 19 December 2006 PIL

Reasons for updating

  • Improved electronic presentation

Updated on 31 July 2006 PIL

Reasons for updating

  • New PIL for medicines.ie

Updated on 17 January 2006 SmPC

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 16 August 2005 SmPC

Reasons for updating

  • New SPC for medicines.ie

Legal category: Product subject to medical prescription which may not be renewed (A)